Is Eli Lilly Stock a Good Investment?
Eli Lilly Investment Advice | LLY |
- Examine Eli Lilly's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Eli Lilly's leadership team and their track record. Good management can help Eli Lilly navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Eli Lilly's business and its evolving consumer preferences.
- Compare Eli Lilly's performance and market position to its competitors. Analyze how Eli Lilly is positioned in terms of product offerings, innovation, and market share.
- Check if Eli Lilly pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Eli Lilly's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Eli Lilly and stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Eli Lilly and is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Eli Lilly Stock
Researching Eli Lilly's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 83.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.69. Eli Lilly recorded earning per share (EPS) of 9.57. The entity last dividend was issued on the 15th of November 2024. The firm had 2:1 split on the 16th of October 1997.
To determine if Eli Lilly is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Eli Lilly's research are outlined below:
| Eli Lilly generated a negative expected return over the last 90 days | |
| Over 83.0% of the company shares are owned by institutional investors | |
| Latest headline from ibtimes.com: Weight-Loss Drugmakers Press Companies To Cover Cost Of Treatment |
Eli Lilly Quarterly Accounts Payable |
|
Eli Lilly uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Eli Lilly and. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Eli Lilly's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 25th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Eli Lilly's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Eli Lilly's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
1996-10-22 | 1996-09-30 | 0.32 | 0.38 | 0.06 | 18 | ||
2015-04-23 | 2015-03-31 | 0.77 | 0.87 | 0.1 | 12 | ||
2015-10-22 | 2015-09-30 | 0.76 | 0.89 | 0.13 | 17 | ||
2012-04-25 | 2012-03-31 | 0.78 | 0.92 | 0.14 | 17 | ||
2010-07-22 | 2010-06-30 | 1.1 | 1.24 | 0.14 | 12 | ||
2015-07-23 | 2015-06-30 | 0.74 | 0.9 | 0.16 | 21 | ||
2013-07-24 | 2013-06-30 | 1 | 1.16 | 0.16 | 16 | ||
2009-10-21 | 2009-09-30 | 1.02 | 1.2 | 0.18 | 17 |
Know Eli Lilly's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Eli Lilly is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Eli Lilly and backward and forwards among themselves. Eli Lilly's institutional investor refers to the entity that pools money to purchase Eli Lilly's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 17 M | State Farm Mutual Automobile Ins Co | 2024-09-30 | 12.6 M | International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | Norges Bank | 2024-06-30 | 11 M | Bank Of America Corp | 2024-06-30 | 10.8 M | Wellington Management Company Llp | 2024-06-30 | 10.8 M | Capital Research Global Investors | 2024-09-30 | 9.3 M | Northern Trust Corp | 2024-09-30 | 8.2 M | Legal & General Group Plc | 2024-06-30 | 7.1 M | Lilly Endowment Inc | 2024-09-30 | 96.9 M | Vanguard Group Inc | 2024-09-30 | 73.8 M |
Eli Lilly's market capitalization trends
The company currently falls under 'Mega-Cap' category with a total capitalization of 715.22 B.Market Cap |
|
Eli Lilly's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.10 | 0.14 | |
| Return On Capital Employed | 0.28 | 0.25 | |
| Return On Assets | 0.08 | 0.12 | |
| Return On Equity | 0.49 | 0.26 |
Determining Eli Lilly's profitability involves analyzing its financial statements and using various financial metrics to determine if Eli Lilly is a good buy. For example, gross profit margin measures Eli Lilly's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Eli Lilly's profitability and make more informed investment decisions.
Eli Lilly's Earnings Breakdown by Geography
Please note, the imprecision that can be found in Eli Lilly's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Eli Lilly and. Check Eli Lilly's Beneish M Score to see the likelihood of Eli Lilly's management manipulating its earnings.
Evaluate Eli Lilly's management efficiency
Eli Lilly has Return on Asset of 0.1395 % which means that on every $100 spent on assets, it made $0.1395 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.6532 %, implying that it generated $0.6532 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Eli Lilly's Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 12.02 | 6.21 | |
| Tangible Book Value Per Share | (1.09) | (1.03) | |
| Enterprise Value Over EBITDA | 64.09 | 36.97 | |
| Price Book Value Ratio | 48.89 | 51.34 | |
| Enterprise Value Multiple | 64.09 | 36.97 | |
| Price Fair Value | 48.89 | 51.34 | |
| Enterprise Value | 494.2 B | 518.9 B |
The decision-making processes within Eli Lilly are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Dividend Yield 0.0071 | Forward Dividend Yield 0.0071 | Forward Dividend Rate 5.2 | Beta 0.43 |
Basic technical analysis of Eli Stock
As of the 21st of November, Eli Lilly shows the Variance of 3.18, standard deviation of 1.78, and Mean Deviation of 1.28. In respect to fundamental indicators, the technical analysis model provides you with a way to check existing technical drivers of Eli Lilly, as well as the relationship between them.Eli Lilly's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Eli Lilly insiders, such as employees or executives, is commonly permitted as long as it does not rely on Eli Lilly's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Eli Lilly insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Gordon Brooks few days ago Disposition of 278 shares by Gordon Brooks of Eli Lilly subject to Rule 16b-3 | ||
Donald Zakrowski over six months ago Payment of 2142 shares by Donald Zakrowski of Eli Lilly subject to Rule 16b-3 | ||
Donald Zakrowski over a year ago Sale by Donald Zakrowski of 670 shares of Eli Lilly | ||
Alfonso Zulueta over a year ago Payment of 9674 shares by Alfonso Zulueta of Eli Lilly subject to Rule 16b-3 | ||
Alfonso Zulueta over a year ago Sale by Alfonso Zulueta of 7000 shares of Eli Lilly |
Eli Lilly's Outstanding Corporate Bonds
Eli Lilly issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Eli Lilly uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Eli bonds can be classified according to their maturity, which is the date when Eli Lilly and has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| LILLY ELI 7125 Corp BondUS532457AM04 | View | |
| LILLY ELI 55 Corp BondUS532457AZ17 | View | |
| US532457BS64 Corp BondUS532457BS64 | View | |
| ELI LILLY AND Corp BondUS532457BU11 | View | |
| ELI LILLY AND Corp BondUS532457BT48 | View | |
| LILLY ELI 31 Corp BondUS532457BP26 | View | |
| ELI LILLY AND Corp BondUS532457BZ08 | View | |
| ELI LILLY AND Corp BondUS532457BV93 | View |
Understand Eli Lilly's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Eli Lilly's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.91) | |||
| Mean Deviation | 1.28 | |||
| Coefficient Of Variation | (536.93) | |||
| Standard Deviation | 1.78 | |||
| Variance | 3.18 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.92) | |||
| Maximum Drawdown | 9.21 | |||
| Value At Risk | (3.55) | |||
| Potential Upside | 2.35 | |||
| Skewness | (0.59) | |||
| Kurtosis | 1.9 |
| Risk Adjusted Performance | (0.13) | |||
| Market Risk Adjusted Performance | (0.91) | |||
| Mean Deviation | 1.28 | |||
| Coefficient Of Variation | (536.93) | |||
| Standard Deviation | 1.78 | |||
| Variance | 3.18 | |||
| Information Ratio | (0.24) | |||
| Jensen Alpha | (0.37) | |||
| Total Risk Alpha | (0.54) | |||
| Treynor Ratio | (0.92) | |||
| Maximum Drawdown | 9.21 | |||
| Value At Risk | (3.55) | |||
| Potential Upside | 2.35 | |||
| Skewness | (0.59) | |||
| Kurtosis | 1.9 |
Consider Eli Lilly's intraday indicators
Eli Lilly intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Eli Lilly stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 0.0289 | |||
| Daily Balance Of Power | (0.34) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 746.42 | |||
| Day Typical Price | 746.24 | |||
| Market Facilitation Index | 21.91 | |||
| Price Action Indicator | (4.27) | |||
| Period Momentum Indicator | (7.51) | |||
| Relative Strength Index | 32.94 |
Eli Lilly Corporate Filings
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 19th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F3 | 18th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Eli Stock media impact
Far too much social signal, news, headlines, and media speculation about Eli Lilly that are available to investors today. That information is available publicly through Eli media outlets and privately through word of mouth or via Eli internal channels. However, regardless of the origin, that massive amount of Eli data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Eli Lilly news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Eli Lilly relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Eli Lilly's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Eli Lilly alpha.
Eli Lilly Historical Investor Sentiment
Investor biases related to Eli Lilly's public news can be used to forecast risks associated with an investment in Eli. The trend in average sentiment can be used to explain how an investor holding Eli can time the market purely based on public headlines and social activities around Eli Lilly and. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Eli Lilly's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eli Lilly and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Eli Lilly news discussions. The higher the estimate score, the more favorable the investor's outlook on Eli Lilly.
Eli Lilly Corporate Directors
| Kathi Seifert | Independent Director | Profile | |
| Jamere Jackson | Independent Director | Profile | |
| Juan Luciano | Lead Independent Director | Profile | |
| Gabrielle Sulzberger | Independent Director | Profile |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.